Skip to main content

Table 6 Clinical, functional, and laboratory data presented as the difference between results at baseline and at 6 months, according to allergy status

From: Real-life experience with benralizumab during 6 months

Variables Non-atopic
(n = 28)
Atopic
(n = 14)
p
Subjective improvement*, n (%) 25 (96) 13 (93) 1
Corticosteroid-dependent at 6 months, n (%) 6 (21.4) 2 (14.3) 0.225
ACT*, md (IR) 8 (3) 5 (4) 0.061
No. of ED visits at 6 months; md (IR) 2 (8) 1 (8) 1
Post-BD FEV1, mL*; md (IR) 307 (295) 379 (343) 0.465
Post-BD FEV1, %*; md (IR) 11 (7) 14 (15) 0.541
FeNO, ppb*; md (IR) 38 (29) 25 (30) 0.158
Blood eosinophil count, cells/μL*; md (IR) 751 (234) 725 (374) 0.650
  1. *Difference between results at baseline and at 6 months
  2. Abbreviations: ACT Asthma Control Test, BD Bronchodilator, ED Emergency department, FeNO Fractional exhaled nitric oxide, FEV1 Forced expiratory volume in 1 s, IR Interquartile range, md Median, ppb Parts per billion